Invivyd, Inc. (IVVD): Capital Expenditures
$155.0K
Year ended 2025-12-31
$1.24M
Trailing 12 months to 2026-06-30
-55.0%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $155.0K | +10.7% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $140.0K | -77.2% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $615.0K | -63.9% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $1.71M | n/m | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $84.0K | n/a | 2023-03-23, From 2021-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | 2025-12-31 | $155.0K | +10.7% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $1.64M | +27.8% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $564.0K | +45.0% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $4.83M | -33.8% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2024-12-31 | $0 | -100.0% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $607.0K | -93.1% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $2.60M | -26.3% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $102.0K | -61.8% |
| Compugen Ltd (CGEN) | 2025-12-31 | $306.0K | +159.3% |
Compare IVVD, PLX, CSBR, VIR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗